Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Business Wire • Dec 11, 2025

Mirum Pharma to buy Bluejay Therapeutics for up to $820 million

Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver disease to its portfolio.

Reuters • Dec 8, 2025

Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript

Seeking Alpha • Dec 8, 2025

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV) to Mirum's portfolio of rare.

Business Wire • Dec 8, 2025

Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026

Mirum Pharmaceuticals has been a big winner in 2025 thanks to the success of its flagship product, Livmarli. Livmarli should continue to gain momentum in 2026.

The Motley Fool • Dec 3, 2025

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study

Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.

Zacks Investment Research • Dec 2, 2025

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). Caused by a mutation of the FMR1 gene, FXS is the most common inherited form of intellectual disability and autism spectrum disorder and affects an estimated 50,000 males in the U.S. and E.U. There are currently no approved therapies for t.

Business Wire • Dec 1, 2025

Biotechs Are On A Big Run, And Two Stocks Have Buy Points

Biotech stocks have a strong presence on the elite IBD 50 list of growth stocks.

Investors Business Daily • Nov 28, 2025